Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia
A recent study indicates that tirzepatide may reduce incident dementia more than semaglutide or SGLT2 inhibitors in adults with type 2 diabetes.
Pain Suzetrigine Data Reveal Reduced Postoperative Opioids
✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainResearchSafetyOpioidPostoperativeDrug EfficacyClinical Trials Why This Matters Suzetrigine's demonstrated…
Pain Suzetrigine Data Reveal Reduced Postoperative Opioids
✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainResearchSafetyOpioidDrug InteractionClinical TrialsPostoperative Why This Matters Suzetrigine's…
Reclassification of marijuana opens doors for much-needed medical research into the … – Seattle PI
The potential reclassification of cannabis from Schedule I to Schedule III could significantly reduce medical research barriers that have limited clinical evidence generation for decades. This regulatory shift would maintain federal oversight while…
Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery – Cannabiz
Pharmaceutical CBD clinical trial development represents important progress in cannabis therapeutics, though patients should maintain realistic expectations about timing and superiority over current protocols. Understanding the distinction between…
UWIFIC and Antigua and Barbuda Medicinal Cannabis Authority Formalise Research and …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPolicyMedical ScienceClinical TrialsAntigua and BarbudaCannabis AuthorityUWIFIC I apologize – I need to…
Federal Marijuana reclassification could reshape medical research and cannabis industry
Federal marijuana rescheduling medical research represents a pivotal moment for cannabis medicine, potentially removing decades-old barriers to rigorous clinical studies. This policy shift could accelerate the development of evidence-based cannabis…
Federal Marijuana reclassification could reshape medical research and cannabis industry
Federal marijuana reclassification medical research changes could remove decades-old barriers to clinical trials and evidence generation. This regulatory shift may fundamentally transform how clinicians approach cannabis medicine with proper scientific…
Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyCannabis Use DisorderClinical TrialsTHCPolicy Why This Matters I don't see a summary…
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchClinical TrialsAnxietySleepCBDSafetyIndustry Clinical Summary IGC Pharma has expanded its Phase 2 CALMA trial by…